DNA demethylating therapy in MDS:: The experience with 5-AZA-2′-deoxycytidine (decitabine).

被引：0
|
作者：
Wijermans, P
Luebbert, M
Verhoef, G
Bosly, A
Ravoet, C
Andre, M
Ferrant, A
Haak, H
机构：
[1] Leyenburg Hosp, Dept Haematol, The Hague, Netherlands
[2] Univ Freiburg, Freiburg, Germany
[3] Univ Grootgasthuisberg, Louvain, Belgium
[4] Mt Godinne UCL, Yvoir, Belgium
[5] Hosp Jolimont, Haine St Paul, Belgium
[6] Hosp Notre Dame, Charleroi, Belgium
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1368
引用
收藏
页码：306A / 306A
页数：1
相关论文
共 50 条
  • [1] An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
    P. W. Wijermans
    M. Lübbert
    G. Verhoef
    V. Klimek
    A. Bosly
    Annals of Hematology, 2005, 84 : 9 - 17
  • [2] An epigenetic approach to the treatment of advanced MDS;: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
    Wijermans, PW
    Lübbert, M
    Verhoef, G
    Klimek, V
    Bosly, A
    ANNALS OF HEMATOLOGY, 2005, 84 (Suppl 1) : 9 - 17
  • [3] Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine)
    Momparler, RL
    SEMINARS IN ONCOLOGY, 2005, 32 (05) : 443 - 451
  • [4] Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)
    Momparler, RL
    SEMINARS IN HEMATOLOGY, 2005, 42 (03) : S9 - S16
  • [5] The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia
    Schaefer, HE
    Lübbert, M
    ANNALS OF HEMATOLOGY, 2005, 84 (Suppl 1) : 67 - 79
  • [6] The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia
    Hans Eckart Schaefer
    Michael Lübbert
    Annals of Hematology, 2005, 84 : 67 - 79
  • [7] The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia
    Hans Eckart Schaefer
    Micheal Lübbert
    Annals of Hematology, 2006, 85 (9) : 637 - 637
  • [8] 5-aza-2′-deoxycytidine, a DNA demethylating agent, inhibits metastatic melanoma invasiveness
    Etievant, Chantal
    Desjobert, Cecile
    Carrier, Arnaud
    Delmas, Audrey
    Tost, Jorg
    Favre, Gilles
    Riond, Joelle
    Arimondo, Paola
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2′deoxycytidine (decitabine).
    Brown, R
    Appleton, K
    Plumb, JA
    McCormick, C
    Lee, C
    Barrett, S
    Tang, A
    Schaetzlein, A
    Kaye, SB
    Judson, I
    McKay, HJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9071S - 9072S
  • [10] Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency
    Lu, Dan
    Hoory, Talia
    Monie, Archana
    Wu, Annie
    Wang, Mei-Cheng
    Hung, Chien-Fu
    VACCINE, 2009, 27 (32) : 4363 - 4369
12345